BeStock  
Stocks › Biotechnology › AVTX

Avalo Therapeutics AVTX

US equityMarket cap rank #3681Biotechnology
$6.76 +$0.01 (+0.15%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $6.76 0.00%
Open$6.65
Prev close$6.75
Day range$6.61 – $7.03
Volume1.18M
Market cap$390.88M
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-3.4x
CheapRich

Near the bottom of its 5-year range · 6th percentile, 5-year average -0.8x

Price / book1.0x
CheapRich

Around its usual level · 51st percentile, 5-year average -0.3x

#1480 of 5329 stocks by PB (1 = cheapest)

Price / sales7,605.2x
CheapRich

Near the top of its 5-year range · 91st percentile, 5-year average 1,838.1x

#5133 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-5x-2x0x3xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$10.79
Price vs. fair value-37.3%Trading below the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 1.03 – -0.30 51% (pricier than usual) #1480 of 5329 (1 = cheapest)
PE -3.43 -3.72 -0.76 6% (cheaper than usual) –
PS 7,605.21 – 1,838.14 91% (pricier than usual) #5133 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on AVTX.

Sign in to join the discussion.

Scroll to Top